Onco-Innovations Partners with Nanosoft Polymers to Advance Cancer Drug ONC010

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has taken a significant step forward in advancing its lead drug candidate, ONC010, by signing a services agreement with Nanosoft Polymers. This partnership is designed to bolster the development of ONC010, a nanoparticle-formulated PNKP inhibitor, by leveraging Nanosoft's expertise in polymer process development, analytical characterization, formulation optimization, scale-up support, and technology transfer. The collaboration focuses on Onco's proprietary PEO-PBCL polymer platform, which is central to the drug's delivery system. As the program progresses through IND-enabling development and prepares for future clinical studies, the agreement aims to establish scalable polymer production processes, enhance analytical methods, and ensure readiness for Good Manufacturing Practice (GMP) manufacturing. This initiative complements ongoing chemistry, manufacturing, and controls (CMC) activities with Dalton Pharma Services and preclinical development efforts at Nucro-Technics, creating a comprehensive development pathway for ONC010 toward first-in-human clinical evaluation.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology targeting solid tumors. ONC010 represents a novel approach using a PNKP inhibitor encapsulated in nanoparticles to potentially enhance the efficacy of cancer therapies. The collaboration with Nanosoft Polymers is a strategic move to strengthen the manufacturing and formulation foundation of ONC010, addressing key challenges in scaling up production and ensuring consistent quality for regulatory submissions and eventual clinical use.

InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, has disseminated this news. InvestorWire offers advanced wire-grade press release syndication for private and public companies, providing access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. This partnership between Onco-Innovations and Nanosoft Polymers marks a pivotal moment in the development of ONC010, bringing the company closer to delivering a potentially transformative cancer treatment to patients.